Steward Financial Group’s ImmunityBio IBRX Stock Holding History

Steward Financial Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-6	Closed	–	–	815
2022 Q4	$0	Buy	+6	New	+$33	﹤0.01%	665

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

SSWM

Sheets Smith Wealth Management Winston-Salem, North Carolina $1B AUM 29.77% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Steward Financial Group's IBRX Position: Q1 2023 in Review

Steward Financial Group sold out of ImmunityBio (IBRX) in Q1 2023, closing a stake of 6 shares.

Steward Financial Group first reported a position in IBRX in Q4 2022 and held it in 1 quarter. The position peaked at $0 in Q4 2022. 146 funds tracked by Wall St. Rank hold IBRX as of Q1 2023.

Steward Financial Group reported no remaining ImmunityBio position as of Q1 2023 after selling out during the quarter.
Steward Financial Group sold 6 ImmunityBio shares in Q1 2023.
Steward Financial Group first reported a position in ImmunityBio in Q4 2022 and held it in 1 quarter.
Steward Financial Group's ImmunityBio position peaked at $0 in Q4 2022.
146 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2023.

Based on Steward Financial Group's 13F filing for Q1 2023, filed 5 May 2023.